Neuren Pharmaceuticals Ltd has released a press release.
Preliminary Final Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- Neuren announces new US patent to be granted for NNZ-2591
- Consolidation/Split - NEU
- Neuren FDA meeting confirms Phase 3 plan for Rett syndrome
- Presentations and publication for Rett syndrome trials
- Change of Director's Interest Notice
Later from Neuren Pharmaceuticals
- S&P DJ Indices Announces March Quarterly Rebalance
- Disclosure under Listing Rule 4.3D
- First patent in Japan granted for Neurens trofinetide
- Neuren announces investment and exclusive negotiation period
- Announcement of buy-back - Appendix 3C
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals